Will treating the overwhelming patient response with medications affect COVID-19 mortality?
Phase 1
Not yet recruiting
- Conditions
- COVID-19Respiratory - Other respiratory disorders / diseasesInflammatory and Immune System - Other inflammatory or immune system disordersInfection - Other infectious diseases
- Registration Number
- ACTRN12620000731998
- Lead Sponsor
- SW Health via the Hunter New England Local Health District
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
Confirmed SARS-CoV-2 infection by any method
Current admission as inpatient to hospital ward for management of COVID-19
Exclusion Criteria
Current use of RAS agent
Known contra-indication to any RAS agent
Participation in another clinical trial for COVID-19 or SARS-CoV-2
Current or previous admission to ICU for COVID-19 management
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does Losartan target in the treatment of severe COVID-19 respiratory complications?
How does Losartan compare to standard-of-care treatments in reducing mortality for hospitalized patients with SARS-CoV-2-induced cytokine storm?
Which biomarkers are associated with patient response to Losartan in managing acute respiratory distress syndrome (ARDS) caused by COVID-19?
What are the potential adverse events of Losartan in patients with comorbid inflammatory and immune disorders during SARS-CoV-2 infection?
Are there combination therapies involving Losartan and other antiviral or immunomodulatory agents being explored for treating multi-system inflammatory syndrome in adults (MIS-A) related to COVID-19?